Deramiocel was turned down by the FDA for a second time on 20 November 2026, and the agency said in public that the main trial's data are unreliable. This brief explains what the trial measured, how its main result moved from P = 0.24 to P = 0.029, and what readers can check for themselves.
The FDA signed its rejection of ivonescimab on 13 November and put the letter online five days later. Summit's announcement gave one reason. The letter gives four, and the first is about where the patients were enrolled.
Witfire has opened witfire.app for researchers who draft with AI. It rewrites a paragraph in a scientist's own voice, then checks in code that every number, unit and citation came back unchanged.
Witfire Elite | Philippines Pharma Watch | BV100 Philippines trial The BV100 Philippines trial plan names two hospitals and a target of 20 participants.…
Witfire Elite | Philippines Pharma Watch | Clinical Catalysts | Nerandomilast Philippines Nerandomilast Philippines trial plans now list three hospitals and a target of…
Witfire Elite | Clinical Catalysts | Trial Design Audit RENGEVITY-201 trial dosing has begun, Veloxis says, with the first participant now treated. The Phase…
16 min read
02 / Breaking Analysis
Consequences, not headlines
Original analysis connecting scientific evidence, regulatory decisions and market value.
Witfire Elite · Clinical Catalysts · Trial Design Audit Pulnovo says two U.S. participants have undergone PULSE-LHD procedures at Henry Ford. The registry estimates…